The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy

References

• Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–1440.10.1016/S0140-6736(09)61497-5
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52(2):155–163.10.1016/j.lungcan.2006.01.006
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–529.10.1016/S1470-2045(10)70112-1
   PubMed Web of Science ®Google Scholar
• Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516–3524.10.1200/JCO.2011.39.9782
   PubMed Web of Science ®Google Scholar
• Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2010, 28(15 Suppl): abstr 7506.
   Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247–255.10.1016/S1470-2045(12)70063-3
   PubMed Web of Science ®Google Scholar
• Blais N, Kassouf E. aintenance therapy for non-small-cell lung cancer. Front Oncol. 2014;19:213. Review.
   Google Scholar
• Mubarak N, Gaafar R, Shehata S, Hashem T, Abigeres D, Azim HA, et al. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer. 2012;12:3825.10.1186/1471-2407-12-423
   Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895–2902.10.1200/JCO.2012.47.1102
   PubMed Web of Science ®Google Scholar
• Yang M, Fan WF, Pu XL, Liu FY, Meng LJ, Wang J. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma. Oncol Lett. 2014;7:227–232.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst. 2000;92:205–216.10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–1474.
   Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–656.10.1097/00000421-198212000-00014
   PubMed Web of Science ®Google Scholar
• Spearman C. The proof and measurement of association between two things. Int J Epidemiol. 2010;39:1137–1150.10.1093/ije/dyq191
   PubMed Web of Science ®Google Scholar
• Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. Am Stat. 1952;47:583–621.10.1080/01621459.1952.10483441
   Web of Science ®Google Scholar
• Fawcett T. ROC graphs: notes and practical considerations for researchers. ReCALL. 2004;31:1–38.
   Google Scholar
• Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 2008;50:419–430.10.1002/(ISSN)1521-4036
   PubMed Web of Science ®Google Scholar
• Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci. 2010;101:161–166.10.1111/cas.2009.101.issue-1
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011;104:1594–1601.10.1038/bjc.2011.129
   PubMed Web of Science ®Google Scholar
• Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non–small-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013;8:19–30.10.1097/JTO.0b013e31827628ff
   PubMed Web of Science ®Google Scholar
• Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011;74:132–138.10.1016/j.lungcan.2011.01.024
   PubMed Web of Science ®Google Scholar
• Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 2011;6:1392–1399.10.1097/JTO.0b013e3182208ea8
   PubMed Web of Science ®Google Scholar
• Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, et al. Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylated synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized phase II trial. J Clin Oncol. 2015;33:2450–2456.
   PubMed Web of Science ®Google Scholar